Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$13.82M$13.82M+38.1% vs Q2 2025 Net Income-$22.86M-$22.86MN/M vs Q2 2025 EPS Diluted-$0.18-$0.18N/M vs Q2 2025 Operating Income-$8,223,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,653,000N/M Margins · derivedOperating margin-59.5%+54.1 pt vs Q2 2025
Net margin-165.5%−30.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end